Navigation Links
Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
Date:5/7/2008

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Bank of America Healthcare Conference on Tuesday, May 13, 2008 at 10:00 a.m. PT in Las Vegas. Michael York, Senior Director of Investor Relations of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
2. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Amylin Pharmaceuticals to Webcast First Quarter Results
4. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
11. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Nashville Fertility ... was elected treasurer for the American Society for Reproductive ... knowledge and research in reproductive medicine. In his ... seat on the executive board and will have a ... Dr. Hill has actively supported ASRM since 1984 when ...
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... December 22, 2014 The Center ... leader of technical training across the life sciences industry, ... Management (SCDM) to provide the organization's members with ... —providing access to the more than 350 sessions across ... with 10% off when registering for a public ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... SPEX ) reported that the Nasdaq Stock Market ... common stock from the Nasdaq,Global Market to the Nasdaq ... on the Nasdaq Capital Market on November 11, 2008., ... market tier designations for,Nasdaq-listed stocks, and presently includes over ...
... Company Will Host a Conference Call Today To Discuss the Data ... ... (Nasdaq: SGMO ) announced today top-line data from its,SB-509-601 clinical ... Therapeutic(TM) program to develop SB-509 for diabetic,neuropathy (DN). The data demonstrate ...
... 10 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality,pharmaceutical grade glucose products in China, ... the three months ended September 30, 2008,after the ... 13, 2008.,Management will conduct a conference call on ...
Cached Biology Technology:Spherix Transfers Stock Listing to Nasdaq Capital Market 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 2Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... An international team of scientists, including researchers at Columbia University ... common malaria parasites require for survival at each stage of ... new approach to combating malaria, one of the world,s deadliest ... of the journal Nature . "Perhaps the ...
... 2013 A Ben-Gurion University of the Negev (BGU) study ... Stress Disorder (PTSD) if their mother is already afflicted. ... & Anxiety , while fewer than 10 percent (8.4 percent) ... fifth (21 percent) of their children presented PTSD symptoms. Children ...
... Spring Harbor, NY A team of researchers at Cold ... DNA called an enhancer element that enables cancerous blood cells ... that is incurable in 70% of patients. Just as ... new class of promising drugs one version of which ...
Cached Biology News:Study finds new vulnerability in malaria parasite 2Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease 2Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease 3
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Request Info...
... Polyoxyethylene Lauryl Ether 30% ... Kathon Preservative. Surfactant. Clear ... immunohistochemistry is 1 mL ... solution added to 400 ...
Biology Products: